Ulcerative Colitis Uc Epidemiology Forecast

DelveInsight’s ‘Ulcerative Colitis (UC) - Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted UC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

UC Understanding

Ulcerative colitis is an inflammatory bowel idiopathic condition that affects the colonic mucosa and is characterized clinically by diarrhea, stomach discomfort, pain, and hematochezia. The extent of the disease is variable and may include either the rectum (ulcerative proctitis), the splenic flexure of the left side of the colon, or the whole of the rectum and bowel. Histologically, the severity of the disorder can also be very complex, varying from minimal to florid ulceration and dysplasia. Carcinoma can be considered developing. The usual histological (microscopic) UC lesion is the crypt abscess, where the crypt’s epithelium breaks down, and polymorphonuclear cells fill the lumen. Approximately 10% of cases of inflammatory bowel diseases exhibit the features of both CD and ulcerative colitis. These are typically known as indeterminate colitis (IC). IC originally refers to IBD cases in which there was difficulty distinguishing between UC and CD in the colectomy specimen. However, IC is increasingly used when a definitive diagnosis of UC or CD cannot be made at colonoscopy, in colonic biopsies or at colectomy.

Continued in the report…

Epidemiology Perspective by DelveInsight

The UC epidemiology division provides insights into the historical and current UC patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In 2021, the overall prevalent cases of UC accessed to be around 2,221,400 in the 7MM, which are expected to grow during the forecast period, i.e., 2022–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted UC epidemiology [segmented as Total Prevalent cases of UC, Total Diagnosed Prevalent cases of UC, Age-specific Diagnosed Prevalent Cases of UC, and Severity-Specific Diagnosed Prevalent Cases of UC in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2022 to 2032.

Country Wise- UC Epidemiology

  • In the United States, the total number of prevalent cases of UC were around 1,017,400 in the year 2021, which are expected to grow during the study period, i.e., 2019–2032.
  • In the year 2021, the total prevalent cases of UC were around 1,020,600 in EU-5, which are expected to grow during the study period, i.e., 2019–2032.
  • In Japan, the total number of prevalent cases of UC were around 183,400 in the year 2021 which are expected to grow during the study period, i.e., 2019–2032.
  • In 2021, mild and moderate-to-severe cases of UC were accounted for around 327,500 and 400,300 in the United States.
  • In the 7MM, the age-specific diagnosed prevalent cases of UC were around 953500; 445,000; 174,800; and 15,900 for the age-groups 18-44, 45-64, 65-84, and ≥85 years respectively, in 2021.

Scope of the Report

  • The UC report covers a detailed overview explaining its causes, symptoms and pathophysiology, diagnosis, and treatment patterns.
  • The UC Report and Model provide an overview of the risk factors and global trends of UC in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of UC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of UC.
  • The report provides the segmentation of the UC epidemiology by total prevalent cases in the 7MM.
  • The report provides the segmentation of the UC epidemiology by diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the UC epidemiology by age-specific diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the UC epidemiology by severity-specific diagnosed prevalent cases of UC in the 7MM.

Report Highlights

  • 11-Year Forecast of UC epidemiology
  • 7MM Coverage
  • Epidemiology Segmentation

KOL-Views

We interview KOLs and SMEs through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the over UC scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to UC?
  • What are the key findings pertaining to the UC epidemiology across the 7MM and which country will have the highest number of patients during the study period (2019–2032)?
  • What would be the total number of patients of UC across the 7MM during the study period (2019–2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2019–2032)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2019–2032)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of UC?

Reasons to buy

The UC Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global UC market
  • Quantify patient populations in the global UC market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for UC therapeutics in each of the markets covered
  • Understand the magnitude of UC population by its severity
  • The UC epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The UC Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Ulcerative Colitis (UC) Epidemiology Overview at a Glance

3.1. Epidemiology Share (%) Distribution of Ulcerative Colitis (UC) in the 7MM in 2019

3.2. Epidemiology Share (%) Distribution of Ulcerative Colitis (UC) in the 7MM in 2032

4. Ulcerative Colitis (UC): Future Prospects

5. Executive Summary of Ulcerative Colitis (UC)

6. Key events

7. Disease Background and Overview

7.1. Introduction

7.2. Types of Ulcerative Colitis (UC)

7.3. Classification of Ulcerative Colitis (UC)

7.4. Signs and Symptoms of Ulcerative Colitis (UC)

7.5. Risk Factors and Causes of Ulcerative Colitis (UC)

7.6. Pathophysiology of Ulcerative Colitis (UC)

7.7. Complications of Ulcerative Colitis (UC)

7.8. Severity Scoring System

7.9. Diagnosis of Ulcerative Colitis (UC)

7.9.1. Differential diagnosis

7.9.2. Antibody blood tests (Biomarkers)

7.10. Diagnostic Guidelines of Ulcerative Colitis (UC)

7.10.1. American College of Gastroenterology (ACG) guidelines

7.10.2. European Crohn’s and Colitis Organization (Journal of Crohn’s and Colitis)

7.11. Treatment and Management of Ulcerative Colitis (UC)

7.11.1. Treatment Algorithm of Ulcerative Colitis (UC)

7.11.2. Diet and Nutrition

7.11.3. Drug Therapies

7.11.3.1. Aminosalicylates

7.11.3.2. Corticosteroids

7.11.3.3. Immunomodulators

7.11.3.4. Janus Kinase (JAK) Inhibitors

7.11.3.5. Biologic Therapies

7.11.4. Other therapies

7.11.5. Surgery

7.11.5.1. Proctocolectomy with Ileal Pouch-Anal Anastomosis (IPAA)

7.11.5.2. Total Proctocolectomy with End Ileostomy

7.11.5.3. Elective Colorectal Cancer Surgery

7.12. Treatment and Management Guidelines of Ulcerative Colitis (UC)

7.12.1. American Gastroenterological Association (AGA) Clinical Practice Guidelines on the Management of Moderate-to-severe Ulcerative Colitis (UC)

7.12.2. American College of Gastroenterology (ACG) Clinical Guideline: Ulcerative Colitis in Adults

7.12.3. British Society of Gastroenterology (BSG) consensus guidelines on the management of inflammatory bowel disease in adults

7.12.4. NICE guidelines

7.12.5. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Epidemiology Methodology

8.3. Assumptions and Rationale

8.4. Epidemiology Scenario: 7MM

8.4.1. Total Prevalent Cases of Ulcerative Colitis (UC) in the 7MM

8.4.2. Total Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in the 7MM

8.5. The United States

8.5.1. Total Prevalent Cases of Ulcerative Colitis (UC) in the United States

8.5.2. Total Diagnosed Cases of Ulcerative Colitis (UC) in the United States

8.5.3. Age-specific Cases of Ulcerative Colitis (UC) in the United States

8.5.4. Severity-specific Cases of Ulcerative Colitis (UC) in the United States

8.6. EU-5 Epidemiology

8.6.1. Total Prevalent Cases of Ulcerative Colitis (UC) in the EU-5

8.6.2. Total Diagnosed Prevalent cases of Ulcerative Colitis (UC) in the EU-5

8.6.3. Age-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in the EU-5

8.6.4. Severity-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in the EU-5

8.7. Japan Epidemiology

8.7.1. Total Prevalent Cases of Ulcerative Colitis (UC) in Japan

8.7.2. Total Diagnosed Prevalent cases of Ulcerative Colitis (UC) in Japan

8.7.3. Age-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in Japan

8.7.4. Severity-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in Japan

9. KOL Views

10. Appendix

10.1. Report Methodology

10.2. Bibliography

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Tables

Table 1: Summary of   Ulcerative Colitis (UC) Epidemiology, and Key Events (2019–2032)

Table 2: Key Events

Table 3: Difference between Crohn’s Disease and Ulcerative Colitis

Table 4: Montreal classification of the extent of UC

Table 5: Montreal classification of severity of UC

Table 6: Mayo Severity Score

Table 7: Diagnostic features of UC

Table 8: Differential Diagnosis for UC

Table 9: Medical Therapy for UC

Table 10: Induction of remission in mildly-to-moderately active ulcerative colitis

Table 11: Maintenance of remission in mildly-to-moderately active ulcerative colitis

Table 12: Induction of remission in moderately-to-severely active ulcerative colitis

Table 13: Maintenance of remission of moderately-to-severely active ulcerative colitis

Table 14: Total Prevalent Cases of Ulcerative Colitis (UC) in the 7MM (2019–2032)

Table 15: Total Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in the 7MM (2019–2032)

Table 16: Total Prevalent Cases of Ulcerative Colitis (UC) in the United States (2019–2032)

Table 17: Total Diagnosed Cases of Ulcerative Colitis (UC) in the United States (2019–2032)

Table 18: Age-Specific Cases of Ulcerative Colitis (UC) in the United States (2019–2032)

Table 19: Severity-specific Cases of Ulcerative Colitis (UC) in the United States (2019–2032)

Table 20: Total Prevalent Cases of Ulcerative Colitis (UC) in the EU-5 (2019–2032)

Table 21: Total Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in the EU-5 (2019–2032)

Table 22: Age-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in the EU-5 (2019–2032)

Table 23: Severity-Specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in the EU-5 (2019–2032)

Table 24: Total Prevalent Cases of Ulcerative Colitis (UC) in Japan (2019–2032)

Table 25: Total Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in Japan (2019–2032)

Table 26: Age-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in Japan (2019–2032)

Table 27: Severity-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in Japan (2019–2032)

List of Figures

Figure 1: Inflammatory bowel disease subsets

Figure 2: Difference between CD and Ulcerative Colitis

Figure 3: Types of UC

Figure 4: Signs and Symptoms

Figure 5: Risk Factors of UC

Figure 6: General factors associated with increased susceptibility of UC

Figure 7: Complications of UC

Figure 8: Biopsy of Colonic Mucosa

Figure 9: Treatment algorithm of Severe Ulcerative Colitis (UC)

Figure 10: Treatment algorithm of Mild to moderate Ulcerative Colitis (UC)

Figure 11: Surgically created ""J"" shaped reservoir

Figure 12: Total Prevalent Cases of Ulcerative Colitis (UC) in the 7MM (2019–2032)

Figure 13: Total Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in the 7MM (2019–2032)

Figure 14: Total Prevalent Cases of Ulcerative Colitis (UC) in the United States (2019–2032)

Figure 15: Total Diagnosed Cases of Ulcerative Colitis (UC) in the United States (2019–2032)

Figure 16: Age-specific Cases of Ulcerative Colitis (UC) in the United States (2019–2032)

Figure 17: Severity-specific Cases of Ulcerative Colitis (UC) in the United States (2019–2032)

Figure 18: Total Prevalent Cases of Ulcerative Colitis (UC) in the EU-5 (2019–2032)

Figure 19: Total Diagnosed Prevalent cases of Ulcerative Colitis (UC) in the EU-5 (2019–2032)

Figure 20: Age-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in the EU-5 (2019–2032)

Figure 21: Severity-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in the EU-5 (2019–2032)

Figure 22: Total Prevalent Cases of Ulcerative Colitis (UC) in Japan (2019–2032)

Figure 23: Total Diagnosed Prevalent cases of Ulcerative Colitis (UC) in Japan (2019–2032)

Figure 24: Age-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in Japan (2019–2032)

Figure 25: Severity-specific Diagnosed Prevalent Cases of Ulcerative Colitis (UC) in Japan (2019–2032)

Forward to Friend

Need A Quote